COMP <GO>
SMTI vs ABBV // EV/EBITDA & P/E VALUATION
Sanara MedTech Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: SMTI 5
— ABBV 7
▲ EV/EBITDA & P/E VALUATION LEADER: SMTI
LAST: $32.92 (+0.11%) • MKT CAP: $302.4M
valuation
29.5x
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SMTI VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SMTI | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 92.70% | 70.20% | +22.50 | SMTI | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.30% | 29.00% | -12.70 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 29.5x | 33.3x | -3.80 | SMTI | /valuation <GO> |
| Free Cash Flow Yield | 0.71% | 3.47% | -2.76 | ABBV | /fcf-yield <GO> |
| Operating Margin | 7.10% | 24.60% | -17.50 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 36.40% | 6.90% | +29.50 | SMTI | /net-margins <GO> |
| Revenue Growth (YoY) | 19.00% | 8.60% | +10.40 | SMTI | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.25 | 5.33 | -2.08 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 27.3 | 65.1 | -37.76 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.8x | 113.1x | -106.30 | SMTI | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $302.4M | $513.86B | -$513.56B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SMTI REV | ABBV REV | SMTI GROSS % | ABBV GROSS % | SMTI FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $103.1M | $61.16B | 92.7% | 70.2% | $2.2M | $17.82B |
| FY 2024 | $86.7M | $56.33B | 90.6% | 70.0% | -$229.6K | $17.83B |
| FY 2023 | $65.0M | $54.32B | — | — | -$3.2M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SMTI // BETA —
ABBV // BETA 1.15